Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Rhea-AI Summary

Eiger BioPharmaceuticals, based in Palo Alto, announced that CEO David Cory will deliver a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference. This presentation will be pre-recorded and accessible on their website starting at 7:00 AM ET on January 10, 2022, for 90 days. Eiger is focused on developing therapies for Hepatitis Delta Virus (HDV) and other rare diseases, with five programs having received FDA Breakthrough Therapy Designation. The company aims to innovate treatments that directly target viral replication processes.

PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference. 

The pre-recorded presentation will be accessible on the Eiger BioPharmaceuticals website at www.eigerbio.com in the Investors section beginning at 7:00 AM ET on Monday, January 10, 2022 and will be available for 90 days. 

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases.  The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.  All five Eiger rare disease programs have been granted FDA Breakthrough Therapy Designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Sri Ryali
Chief Financial Officer
Email: sryali@eigerbio.com
Phone: 1-650-272-6138 ext. 1007

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-hc-wainwright-bioconnect-2022-virtual-conference-301452523.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is Eiger BioPharmaceuticals presenting at the H.C. Wainwright BioConnect 2022 Conference?

Eiger BioPharmaceuticals will present a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference.

When will the Eiger presentation be available for viewing?

The presentation will be available on Eiger's website starting at 7:00 AM ET on January 10, 2022, for 90 days.

What is the focus of Eiger BioPharmaceuticals' therapies?

Eiger focuses on developing therapies for Hepatitis Delta Virus (HDV) and other serious rare diseases.

How many Eiger programs have FDA Breakthrough Therapy Designation?

Eiger has five rare disease programs that have received FDA Breakthrough Therapy Designation.

Where can I find more information about Eiger BioPharmaceuticals?

Additional information about Eiger can be found on their website at www.eigerbio.com.